Understanding the US FDA’s Special Designations and Approval Pathways
Recognizing the challenges of drug development, the US FDA has established several special designations and…
Article Date
January 26, 2026
This article is featured on another website.
Go to article
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
September 11, 2026
Data Governance and Geopolitics: The New Operational Reality of Global Clinical Trials
Part 4 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
September 11, 2026
Data Governance and Geopolitics: The New Operational Reality of Global Clinical Trials
Part 4 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…